Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
6.40
+0.19 (3.06%)
At close: Nov 18, 2026, 4:00 PM EST
6.50
+0.10 (1.56%)
After-hours: Nov 18, 2026, 7:30 PM EST
Agenus Employees
Agenus had 81 employees as of December 31, 2025. The number of employees decreased by 235 or 74.37% compared to the previous year. That makes Agenus the 32,638th largest employer in the world and 4,224th in the United States.
Employees
81
Change (1Y)
-235
Growth (1Y)
-74.37%
Revenue / Employee
$1,653,654
Profits / Employee
$377,938
Market Cap
289.58M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 81 | -235 | -74.37% |
| Dec 31, 2024 | 316 | -73 | -18.77% |
| Dec 31, 2023 | 389 | -144 | -27.02% |
| Dec 31, 2022 | 533 | 92 | 20.86% |
| Dec 31, 2021 | 441 | 82 | 22.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Allogene Therapeutics | 152 |
| Enanta Pharmaceuticals | 120 |
| Inovio Pharmaceuticals | 112 |
| Editas Medicine | 87 |
| SAB Biotherapeutics | 86 |
| Scribe Therapeutics | 82 |
| Century Therapeutics | 78 |
| AgomAb Therapeutics NV | 62 |
AGEN News
- 9 days ago - Agenus price target raised to $16 from $14 at B. Riley - TheFly
- 12 days ago - Agenus announces new findings from Phase 1b C-800-1 trial of BOT - TheFly
- 12 days ago - Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026 - Business Wire
- 13 days ago - Agenus Transcript: Fireside chat - Transcripts
- 13 days ago - Agenus reports Q3 revenue $31.5M, consensus $28.23M - TheFly
- 13 days ago - Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study - Business Wire
- 13 days ago - Agenus Earnings release: Q3 2026 - Filings
- 13 days ago - Agenus Quarterly report: Q3 2026 - Filings